Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®
22 févr. 2023 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer
09 janv. 2023 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...